Clinical Trial

Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
prospective observational cohort study to explore the relationship between PGE2 metabolite levels and the development of hemodynamically significant PDA in preterm neonates.
Trial Details
NCT Number NCT07338370
Lead Sponsor Ain Shams University
Conditions Neonatal Prematurity, Patent Ductus Arteriosus in Preterm Infants, Prostaglandins
Enrollment 34 participants
Start Date 2026-01
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-13